---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-024292"
form_type: "8-K"
ticker: "ERAS"
cik: "0001761918"
company_name: "Erasca, Inc."
filed_at: "2023-05-25T23:59:59+00:00"
generated_at: "2026-06-14T14:46:50.746927+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Erasca reports early data on ERAS-007 combos: 40% response in BRAFm CRC; stops palbociclib combo in KRASm tumors

## Summary
- ERAS-007 + encorafenib + cetuximab in BRAF V600E CRC: 40% response (2/5) at 100mg BID-QW, 29% overall across doses.
- Combination generally well-tolerated with mostly low-grade AEs; one DLT (Grade 3 macular edema) at highest dose.
- ERAS-007 + palbociclib showed no clinical activity in KRAS/NRAS mutant CRC and KRASm PDAC; company will not pursue combo.
- Additional Phase 1b HERKULES-3 data in BRAF-mutated CRC expected between H2 2023 and H1 2024.
- PK exposures of ERAS-007, encorafenib, cetuximab comparable to monotherapy, no significant drug-drug interactions.

## SEC filing metadata
- accession: 0000950170-23-024292
- form_type: 8-K
- ticker: ERAS
- cik: 0001761918
- company_name: Erasca, Inc.
- filed_at: 2023-05-25T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1761918/000095017023024292/0000950170-23-024292-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1761918/000095017023024292/eras-20230525.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-024292
- JSON: https://secwatch.observer/filing/0000950170-23-024292.json
- Plain text: https://secwatch.observer/filing/0000950170-23-024292.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.